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Background: Few studies have used standardized QOL instruments to assess the quality of life (QOL) in Gilles de la
Tourette Syndrome (GTS) patients. This work investigates the QOL of adult GTS patients and examines the
relationships between physical and psychological variables and QOL.
Methods: Epidemiological investigation by anonymous national postal survey of QOL of patients of the French
Association of Gilles de la Tourette Syndrome (AFGTS) aged 16 years or older. The clinical and QOL measures were
collected by four questionnaires: a sociodemographic and GTS-related symptoms questionnaire, the World Health
Organization Quality Of Life questionnaire (WHOQOL-26), the Functional Status Questionnaire (FSQ), and a self-rating
questionnaire on psychiatric symptoms (SCL-90), all validated in French. We used stepwise regression analysis to
explicitly investigate the relationships between physical and psychological variables and QOL domains in GTS.
Results: Questionnaires were posted to 303 patients, of whom 167 (55%) completed and returned them. Our results,
adjusted for age and gender, show that patients with GTS have a worse QOL than the general healthy population.
In particular, the “Depression” psychological variable was a significant predictor of impairment in all WHOQOL-26
domains, psychological but also physical and social.
Conclusions: The present study demonstrates a strong relationship between QOL in GTS and psychiatric symptoms,
in particular those of depression.
Keywords: Gilles de la Tourette Syndrome, Quality of life, Physical and psychological health status, Psychology,
Psychiatric disorders, DepressionBackground
Gilles de la Tourette syndrome (GTS) is a developmental
neuropsychiatric disorder characterized by multiple
motor tics and one or more vocal tics occurring over a
period of more than one year [1]. The age of onset of
GTS ranges from 2 to 18 years, with a commonly
reported mean of 7 years. Recent studies have suggested
that GTS occurs in at least 1% of the worldwide popula-
tion, with a male/female ratio of 3:1, and a prevalence
between 0.4% and 3.8% for ages from 5 to 18 years [2].* Correspondence: ijalenques@chu-clermontferrand.fr
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reproduction in any medium, provided the orThus, the disease begins during childhood and develops
in a succession of periods with variable aggravation or
remission of the tics. Most patients show improvement
at the end of adolescence, but symptoms can persist into
adulthood in about one third of those affected [3]. It is
now recognized that GTS is a complex pathology with a
high occurrence of comorbid neuropsychiatric disorders
(up to 90% of GTS patients) [2,4-7]. The most common
are attention-deficit/hyperactivitiy disorder (ADHD) and
obsessive-compulsive disorder (OCD) [8]. Depression,
anxiety, self-injurious behaviours (SIB) and conduct dis-
orders (CD) are also common in adult GTS subjects
[7,9]. Major handicaps for patients affected by GTS are
delayed diagnosis, non-specialist management, and inad-
equate educational and social support [8].
Recent studies have described the psychological, famil-
ial, social and educational impact of tics and associatedral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adult GTS patients only a few studies have used standar-
dized QOL instruments for assessment. Importantly, the
two major reports on the subject [13,14] were made in
tertiary care centres whereas our study investigated the
QOL of GTS patients and examined the relationship be-
tween physical and psychological variables and quality of
life in a consecutive, unselected sample. Specifically, we
conducted an anonymous national postal survey of QOL
among members of the French Association of Gilles de
la Tourette Syndrome (AFSGT) aged 16 years or older.
Members completed and returned self-rating question-
naires that had been validated in French and thus could
be relied on to correctly estimate health and social pro-
blems. We expected an impairment of all domains of
QOL and a consistent relationship with the occurrence
of comorbid psychiatric disorders.
Methods
Patients
A total of 303 patients aged 16 years or older of the
AFSGT were identified and sent self-rating question-
naires in March 2007, with a second anonymous mailing
in June 2007 [15]. Only fully completed questionnaires
were used. Of the 303 patients, 125 completed and
returned questionnaires after the first mailing, and 42
after the second. Thus 167 patients were included in this
study. The study received approval from the inter-
regional ethics committee of Rhône-Alpes-Auvergne in
Grenoble. Patient information was recorded on the first
page of the questionnaire. Participants gave informed
consent by returning the questionnaire.
Data collection procedures and instruments
The clinical and QOL measures were collected by four
questionnaires: a sociodemographic and GTS-related
symptoms questionnaire, the WHOQOL-26 (World
Health Organization Quality Of Life) questionnaire, the
FSQ (Functional Status Questionnaire), and the SCL-90
(self-rating questionnaire on psychiatric symptoms), all
validated in French [16-22].
Sociodemographic and GTS-related symptoms
questionnaire
At baseline, socio-demographic data on gender, age, life-
style, marital status, education, and employment status
were collected. Clinical data related to motor and vocal
tics, and their severity, age at onset, age at diagnosis and
daily frequency. Management was identified by questions
about treatment, specialist or generalist management,
age at initiation of management, psychotherapy, and
compliance with care. The patient’s own subjective view
about the severity of tics and of GTS was collected by
visual analogue scales (VAS): range no tic to maximumseverity of tics; no GTS to maximum severity of GTS.
When responding to a VAS item, respondents specified
their level of agreement with a statement by indicating a
position along a continuous line between two end-
points. The sensitivity and reproducibility of the VAS
results are broadly satisfactory [23].
SCL-90 R (self-rating questionnaire about psychiatric
symptoms)
The SCL-90 R is the latest version of a self-report inven-
tory of symptomatic complaints developed from previ-
ous inventories [16]. It is a 90 item instrument which
was chosen to measure 10 postulated factors: depression,
somatisation, anxiety, phobic anxiety, obsessive-compul-
sive, interpersonal sensitivity, anger-hostility, psychoti-
cism, paranoid ideation, and sleep and concentration
difficulties. We used the French translation by Pariente
and Guelfi [21]. Each of the 90 items corresponds to a
sentence which the subject rates on a 5-point scale: “1:
not at all” to “5: extremely” according to his or her mood
state over the previous 7 days. The SCL-90 R manual
gives a global score (from 90-450) and specific scores for
each domain. It also provides three other indexes com-
puted from the item scores: the General Symptomatic
Index (GSI), which represents overall severity, the Posi-
tive Symptom Total (PST), which assesses the diversity
of symptoms, and the Positive Symptom Distress Index
(PSDI), which takes into account the patient’s own sub-
jective view about the degree of discomfort for each
symptom. Its validity is well documented [24-26].
WHOQOL-26 (World Health Organization Quality Of Life)
The WHOQOL-Bref or WHOQOL-26 is an abbreviated
version of the WHOQOL-100 quality of life assessment
instrument, which is a generic, multidimensional meas-
ure for subjective assessment of QOL [22,27-29] The
WHOQOL-26 was developed to allow a brief and accur-
ate assessment of QOL in routine clinical work, large
scale-epidemiological studies and clinical trials [22]. It
comprises one question for each of the 24 facets in the
WHOQOL-100 belonging to one of the following
domains: physical health (7 items), psychological health
(6 items), social relationships (3 items) and environment
(8 items). Facets incorporated within the “physical” do-
main are: activities of daily living, dependence on medi-
cinal substances and medical aids, energy and fatigue,
mobility, pain and discomfort, sleep and rest, and work
capacity. “Psychological” facets allow assessment of bod-
ily image and appearance, negative and positive feelings,
self-esteem, spirituality and personal beliefs, and capacity
of learning, memory and concentration. Other facets
allow detailed assessment of “social relationships”: per-
sonal relationship, social support, sexual activities; and
of “environment”: financial resources, physical safety,
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environment, opportunities of acquiring new informa-
tion and skills, participation in and opportunities for
leisure activities, transport, and quality of environment
(e.g. pollution, noise). Two further questions are global
indicators of QOL and satisfaction with health. In total,
it has 26 items, each with a five-point Likert scale. High
scores indicate good QOL. Apart from the four domain-
and two well-being scores an overall score is used in-
cluding all items. The time of reference is the previous
two weeks. In earlier research, analyses of the internal
consistency, item-total correlations, discriminant valid-
ity, and construct validity through confirmatory factor
analysis, indicated that the WHOQOL-26 had good to
excellent reliability and validity in a population of psy-
chiatric patients [22,30]. We used the French translation
by Leplège [18].
FSQ (Functional Status Questionnaire)
The Functional Status Questionnaire (FSQ) is a brief,
standardized, self-administered questionnaire designed
to provide a comprehensive and feasible assessment of
physical, psychological, social and role function in ambu-
latory patients [17,19,20]. It comprises questions for
each of the following sections: physical functions (basic
Activities of Daily Living or ADL e.g. taking care of one-
self, moving in or out a bed or chair, walking indoors;
intermediate ADL e.g. running, home maintenance,
shopping, driving), mental health (items ask patients
how they viewed their personality, e.g. nervous/peaceful,
downhearted/happy), work performance (quantitative or
qualitative limitations because of impaired health), social
activities (difficulty visiting with relatives or friends, par-
ticipating in community activities, taking care of other
people) and the quality of their social interactions (iso-
lating oneself, acting affectionate toward others, being ir-
ritable toward those around, making unreasonable
demands on family or friends). The FSQ can be com-
pleted and computer-scored in minutes to produce a
one-page report which includes six summated-rating
scale scores and six single-item scores. The clinician can
use this report both to screen for and to monitor
patients' functional status. In earlier research, findings
demonstrated that the FSQ produces reliable sub-scales
with construct validity [17]. We used the validated
French translation by Martin [19,20].
Since the QOL assessment by postal survey included
self-rating questionnaires, a pilot study was needed to
assess their feasibility. We sent questionnaires to 21
patients attending the GTS specialized follow-up clinic
of university hospitals in Clermont-Ferrand and Paris.
Twenty questionnaires were returned fully completed.
The remaining one was unusable owing to numerous in-
valid answers. Four others had one answer missing,which did not invalidate overall assessment. The mean
time to complete the questionnaires was 31.5±10.5 min-
utes. Because the questionnaires were satisfactorily com-
pleted by subjects, only a few adjustments were made to
make them easier to read and more attractive.Statistical analysis
Data were analysed using the Statistical Package for So-
cial Sciences (SPSS, version 12.0 for Windows). All stat-
istical tests used a two-sided risk α of 5%.
Means of each dimension of the WHOQOL-26 were
compared between GTS patients (n = 167) and data
extracted from the National Institute of Prevention and
Health Education (NIPHE), using Student’s t-test. NIPHE
is a nationally representative sample (n = 3560) obtained
in national telephone surveys that cover the develop-
ment of knowledge, opinions, attitudes and behaviours
of the French population in the field of health [30].
Results were confirmed by multiple linear regression
adjusted for age and gender.
Stepwise regression analyses adjusted for age and gen-
der were performed to determine in the GTS sample the
relationship between physical and psychological variables
(VAS Tic, VAS GTS, SCL-90 R independent variables)
and quality of life and functional status (domain scores
dependent variables).Results
The sociodemographic characteristics of the 167 patients
are presented in Table 1. The mean age was 29.3 years
(SD 12.0, range 16-68). The mean age at onset of disease
was 8.8 years (SD 4.3). The mean age at diagnosis of dis-
ease was 17.5 years (SD 9.4). Eighty nine per cent of
patients (n = 148) reported tics at the time of the study.
About 32% of the patients had no medication. The main
drug treatments were atypical neuroleptics (54.5%),
antidepressants (38.3%), anxiolytics (17.4%) and psy-
chostimulants (3%); 47.3% had neurological specialist
management, 31.1% psychiatric and 10.2% psychological
management.
The mean score of severity of tics collected by VAS
was 43.4 (SD 22.9); 141 of the 148 patients reporting tics
at the time of the study completed the score.
Table 2 shows the SCL-90 R results. All factors were
impaired. The most affected factors were the obsessive-
compulsive factor, interpersonal sensitivity, depression
and hostility.
Results of the WHOQOL-26 of GTS patients com-
pared to those of the healthy population (NIPHE sam-
ple) are shown in Table 3. In comparison to a healthy
population, GTS patients had significantly lower scores
in all domains indicating worse QOL: physical (t-Test,
t = -5.57, p<0.0001), psychological (t-Test, t = -8.29,
Table 1 Sociodemographic characteristics of patients with













No exam 29 17.4
Graduate Certificate 32 19.2
Technical training 37 22.2
Bachelor 28 16.8




At school, at university 48 28.7
Normal employment 11 6.6




Table 2 Psychiatric symptoms: mean scores in the
different factors of the SCL-90R
Factors mean SD
Obsessive-compulsive 1.23 0.78
Interpersonal sensitivity 1.22 0.78
Depression 1.08 0.78
Hostility 1.04 0.80
Paranoid ideation 0.94 0.90
Anxiety 0.91 0.75
Sleep and concentration difficulties 0.85 0.71





Most affected factors indicated by higher scores.
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ment (t-Test, t = 2.56, p<0.01).
The six FSQ mean summated-rating scale scores are
given in Table 4. GTS patients mentioned good physical
function (mean basic ADL 96.02, SD 10.17; mean inter-
mediate ADL 86.86, SD 18.22). Mean summated-rating
scale score for psychological functions was clearly
impaired (mean 52.92, SD 19.36). The two mean
summated-rating scale scores for work performance and
social activities were not dramatically impaired (mean
work performance 80.83, SD 18.65; mean social activities
83.47, SD 22.96) but patients reported poor quality of
social interactions (mean 69.32, SD 15.22).
Table 5 gives figures about the influence of the severity
of tics and GTS disease (VAS) and psychiatric symptoms
(SCL90R) upon each dimension of the WHOQOL 26,
when adjusted for age and gender. The variable “depres-
sion” was significantly associated with all WHOQOL-26
domains (Physical health domain: p<0.0001; Psycho-
logical health domain: .p<0.0001; Social relationshipsdomain: p<0.0001; Environment domain: p<0.0001).Fig-
ures about the influence of the severity of tics and GTS
disease (VAS) and Psychiatric Symptoms (SCL90R) upon
each dimension of the FSQ, with results adjusted for age
and gender, are given in Table 6. The variable “Depres-
sion” was significantly associated with the domains of
“mental health” (p<0.0001) and “quality of interactions”
(p<0.0001) FSQ.
We examined whether there was an interaction be-
tween tic severity and depression SCL-90R domain score
in predicting QOL. Hierarchical linear regressions were
computed, with QOL and functional status domain
scores as independent criteria, and adjusted for age. In
step 1, the tic severity and depression SCL-90R score
were entered; in step 2 their interaction was entered.
There was no significant effect of the interaction be-
tween tic severity and depression for all QOL domains.
Similar non-significant results were found with FSQ
dimensions (Tables 7 and 8).
Discussion
Our survey shows that GTS patients had a worse QOL
than the general healthy population. These results are in
agreement with those of two other studies performed on
QOL in adults GTS. The first [13] measured QOL in
103 patients with a generic self-rating questionnaire SF-
36 (Medical Outcome Study 36-Items Short-Form
Health Survey), and a generic hetero-questionnaire
QOLAS (Quality of Life Assessment Schedule). The
authors concluded that patients with GTS had signifi-
cantly worse QOL than the general population in all
subscales of the SF-36 except the “vitality” subscale, but
had better QOL than 145 patients with intractable epi-
lepsy. However, QOL in GTS patients could be overesti-
mated. The QOLAS was initially developed to assess
Table 3 Comparison of WHOQOL-26 results of GTS patients with healthy population of NIPHE sample
WHOQOL-26 Domains GTS Mean (SD) NIPHE sample Mean (SD) Student’s test p value
Physical health 13.77 (3.30) 15.21 (2.52) <0.0001
Psychological health 12.18 (3.05) 14.15 (2.31) <0.0001
Social relationships 12 .97 (3.93) 15.31 (2.51) <0.0001
Environment 14.64 (2.69) 15.18 (2.36) <0.001
SD: standard deviation.
WHOQOL-26: World Health Organisation Quality of Life 26.
NIPHE: National Institute of Prevention and Health Education.
Worse QOL indicated by lower scores.
Table 5 Influence of the severity of tics, GTS and
psychiatric symptoms on each dimension of QOL
WHOQOL-26 domains Independent variables R2 total p value
Physical health Depression* 0.4925 <0.0001
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underestimate health problems in a population of GTS
patients. Secondly, the social dimension of the SF-36 is
limited. SF-36 allows assessment of the limitations in
functioning with a bias towards basic activities of every-
day life and work activities, but it does not capture
restrictions on activities due to the social stigma of GTS
and feelings of embarrassment. In the second study, of
Müller-Vahl et al. [14], which included 200 patients, the
social dimension was not assessed. The quality of life
scale used, the EQ-5D [31], is a very simple tool allowing
for a very general assessment of quality of life and pos-
sesses only one item per dimension. It is mostly used in
medico-economic studies [32]. Lastly, Müller-Vahl et al.
[14] did not assess obsessive-compulsive symptoms
whereas this dimension is represented in the SCL90R, as
is depression, which Müller-Vahl et al. assessed using
the Beck Depression Inventory (BDI) [14].
Studies of GTS in children and adolescents provide
evidence of relationships between QOL and psychiatric
comorbidity. In the study of Storch et al. 2007, for ex-
ample, QOL as assessed by children and their parents
seems to be influenced by the presence of psychiatric
symptoms [10]. With relation to depressive symptoms in
children, Eddy et al. 2010 reported that GTS patients
had more depressive symptoms than control subjectsTable 4 Functional Status Questionnaire (FSQ) mean GTS
patients summated-rating scale scores
FSQ Sections GTS Mean (SD) Qualitative data
Physical functions:
Basic ADL 96.02 (10.17) Good
Intermediate ADL 86.86 (18.22) Good
Mental health 52.92 (19.36) Clearly pathological
Work performance 80.83 (18.65) Warning zone
Social activities 83.47 (22.96) Warning zone
Quality of interactions 69.32 (15.22) Pathological
SD: standard deviation; ADL: Activities of Daily Living; FSQ: Functional Status
Questionnaire.
Summated-rating scale scores for basic ADL: “Good” 88-100, “Warning zone”
0-87; for intermediate ADL: “Good” 78-100, “Warning zone” 0-77;for mental
health: “Good” 71-100, “Warning zone” 0-70; for work performance: “Good”
79-100, “Warning zone” 0-78; for social activities: “Good” 79-100, “Warning
zone” 0-78; for quality of interactions: “Good” 70-100, “Warning zone” 0-69.and controls with epilepsy. However, results from these
studies in children have yet to show a causal relationship
between depression, tic severity and QOL [33].
We chose the WHOQOL-26 because it has good to
excellent reliability and validity in neuropsychiatric
patients [22]. It is easily administered and does not im-
pose a great burden on the respondent. Furthermore, it
is a sound cross-culturally valid assessment of QOL
[22,27-29]. As social functioning is a key dimension in
assessing QOL in GTS patients, we used the FSQ, which
allows a distinction between good activities of everyday
life, impaired social activities and work performance,
and patients’ subjective views about poor quality of so-
cial interactions [17,19,20]. Using these different scales,
which are reliable in estimating health and social pro-
blems in a patient group with a young mean age, we
were able to show a dramatic impact of GTS in all
domains (physical, psychological, social) of QOL and
point up the need for a multidisciplinary approach to
GTS. Recently, Cavanna et al [34] constructed and vali-
dated a new disease-specific patient-reported scale forVAS GTS 0.6003 0.0027
Somatisation* 0.6120 0.0478
Psychological health Depression* 0.5447 <0.0001




VAS GTS 0.4640 0.0074
Environment Depression* 0.2332 <0.0001
VAS GTS 0.2929 0.0009
Somatisation* 0.3355 0.0039
VAS GTS visual analogue mean scores severity of Gilles de la Tourette
Syndrome Psychiatric symptoms: SCL-90R: Symptom Checklist 90 Revised
WHOQOL-26: World Health Organisation Quality of Life-26; stepwise regression
analysis.
* One of 10 factors of SCL-90R.
Table 6 Influence of the severity of tics, GTS and
psychiatric symptoms on dimensions of the FSQ
FSQ Domains Independent variables R2 total p value
Physical - basic ADL Psychotic* 0.0961 0.0002
Physical-intermediate ADL Phobic anxiety* 0.2269 <0.0001
VAS GTS 0.3301 <0.0001
Somatisation* 0.3544 0.0254
Mental health Depression* 0.5925 <0.0001
VAS GTS 0.6154 0.0050
Work performance Obsessive-compulsive* 0.2248 <0.0001
VAS TIC 0.2674 0.0432










FSQ: Functional Status Questionnaire.
ADL: Activities of Daily Living.
VAS GTS visual analogue mean scores severity of Gilles de la Tourette
Syndrome.
VAS TIC: visual analogue mean scores of severity of Tics.
SCL-90R: Symptom Checklist 90 Revised of psychiatric symptoms.
Stepwise regression analysis.
*One of 10 factors of SCL-90R.
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GTS-QOL. Response data analysis and item reduction
methods led to a final 27-items with four subscales (psy-
chological, physical, obsessional and cognitive) which
take into account the complexity of the clinical picture
of GTS. As a result, the GTS-QOL contains only three
items covering questions of reverberations on social in-
tegration and support, and one item covering difficulties
in ADL. Physical and cognitive factors contain many
items covering specific symptoms of GTS (movement
dyscontrol, phonic tics, repeating words and actions,
copying people, unpleasant thoughts). The cognitive do-
main has four items (covering memory, losing items, dif-
ficulty finishing tasks and concentration) which are not
contained in the generic QOL scales used in our study.
The GTS-QOL has not yet been validated in French and
could not be used in our study as it was published after
the clinical data collection phase.
We sought to determine the relationship between QOL
or functional status and severity of tics and GTS, and psy-
chiatric comorbidities using a stepwise regression model
adjusted for age and gender. In our study, the “depression”
psychological variable is the only one significantly asso-
ciated with all QOL domains of the WHOQOL-26, as
in the findings of Müller-Vahl et al.[14] who, usingmultivariate analysis, reported that depression assessed by
the BDI was the only variable significantly associated with
reduced quality of life. The study of Elstner et al.[13] also
reported an association between depression or anxiety and
impaired QOL in adult GTS patients, although other fac-
tors contributed to QOL. However, these correlations
were not calculated by multivariate analysis. Two investi-
gations of young patients with GTS reported that generic
Health Related Quality Of Life (HR-QOL) was primarily
predicted by the comorbidities of OCD and ADHD rather
than by tic severity [11,35]. The study of Cavanna et al.
[34] confirms the relationships between QOL and physical
and psychiatric variables using disease-specific patient-
reported scales and standardized evaluations: GTS-QOL
standardized mean scores were mainly affected by psy-
chological and cognitive problems, followed by physical/
activities of daily living and obsessive-compulsive themes.
We explored mediational relationships between de-
pression, tic severity and QOL by hierarchical linear re-
gression analysis. There was no significant effect of the
interaction between depression and tic severity on the
QOL domain scores.
It is noteworthy that depression and not tic severity
was the main predictor of reduced QOL in both our
study and that of Müller-Vahl et al. This should also
suggest that tic severity is not directly related to mood,
an observation that is in accordance with empirical clin-
ical practice and deserves further exploration. A parallel
can be drawn with Parkinson’s disease (PD), in which
several studies have shown that reduced quality of life is
mainly a function of depression and not motor status
[36]. In contrast to GTS, however, depression in PD
patients is not considered purely reactive but has an in-
trinsic organic nature due to the degeneration of nora-
drenergic and serotoninergic brainstem neurons. One
might therefore speculate if increased depression in GTS
is merely a reflection of psychosocial impairment in the
broadest sense or whether there might be an organic
susceptibility for depression and anxiety. The sex ratio
observed in our sample (3:1) corresponds to that of
other patient series [2,34]. We found, like other authors
[13], that there was a high unemployment rate (19.2%)
and poor academic achievement among patients (17.4%
left school without qualifications). As in other studies,
many patients lived with their family. Our sample was
slightly younger than other populations included in pre-
vious studies, with the exception of that of Elstner et al.
(29.3 years SD 12 in our study, 30.7 years SD 9.7 in
Cavanna et al. [34], 28.7 years SD 8.6 in Elstner et al.
[13,14], 34.9 years SD 11.8 Müller-Vahl et al. [14]). This
can be partly explained by the choice of our sample:
most members of the AFGST are children (not included
in our study) and young subjects living with their fam-
ilies. Our patients are characteristic in that they are
Table 7 Hierarchical linear regression analyses adjusted for age predicting WHOQOL-26 domain scores from SCL-90R
depression score
Order of entry β Significance of β R2 ΔR2 ΔF Significance of ΔF
(p-value) (p-value)
Physical health
Step 1 0.5428 0.5428 53.43 <0.0001
VAS TIC -0.30 0.0053
SCL-90R depression score -0.71 <0.0001
Step 2 0.5444 0.0016 0.48 0.4898
Interaction of VAS TIC and SCL-90R depression score 0.13 0.4898
Psychological health
Step 1 0.5504 0.5504 55.10 <0.0001
VAS TIC -0.12 0.2590
SCL-90R depression score -0.89 <0.0001
Step 2 0.5420 0.0048 1.45 0.2303
Interaction of VAS TIC and SCL-90R depression score 0.22 0.2303
Social relationships
Step 1 0.2926 0.2926 18.75 <0.0001
VAS TIC -0.06 0.6402
SCL-90R depression score -0.58 0.0010
Step 2 0.2931 0.0005 0.10 0.7509
Interaction of VAS TIC and SCL-90R depression score 0.07 0.7509
Environment
Step 1 0.2533 0.2533 15.38 <0.0001
VAS TIC -0.24 0.0792
SCL-90R depression score -0.60 0.0008
Step 2 0.2599 0.0065 1.19 0.2769
Interaction of VAS TIC and SCL-90R depression score 0.25 0.2769
VAS TIC: visual analogue mean scores of severity of Tics; SCL-90R: Symptom Checklist 90 Revised of psychiatric symptoms.
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disease and not the most severe cases attending GTS
specialized follow-up clinics of university hospitals. We
believe, therefore, that our sample is more representative
of the general GTS population.
The results of the present study are in accordance with
those of previous studies but several limitations should
be considered when reviewing these findings. Our data
were collected by an anonymous national postal survey
of individuals who belonged to a patient association and
we therefore did not know if all the patients fulfilled
DSM-IV-TR criteria [1] for the diagnosis of GTS and for
various GTS-associated psychiatric disorders. We ques-
tioned patients about their age at the time of diagnosis.
Most patients nevertheless had specialist management
(neurological and/or psychiatric and/or psychological)
and we assessed psychological and psychiatric com-
plaints by a validated self-report inventory, the SCL-90
R. Although we used VAS for assessing tic severity,
which is a reproducible subjective scale sensitive tochange in the assessment of symptoms, severity was not
assessed by standardized and structured instruments
such as the Yale Global Tic Severity Scale (YTGSS).
Conclusion
The present study demonstrates a strong relationship
between QOL in adult GTS patients and psychiatric
symptoms, especially depression. This is important given
that the main psychiatric comorbidity in GTS in terms
of frequency is OCD but, with regard to QOL, we need
to pay more attention to depression. We therefore
propose that future studies perform a precise analysis of
the relationships between GTS and depression, as has
been previously suggested for ADHD and OCD [31]. It
is also important to advocate a multidisciplinary ap-
proach, including the involvement of psychiatrists, to as-
sess GTS patients with depression and other psychiatric
comorbidities. A powerful treatment for depression, con-
current with tic treatment, may improve patient func-
tioning and QOL more effectively.
Table 8 Hierarchical regression analyses adjusted for age predicting FSQ dimension scores from SCL-90R depression
score
Order of entry β Significance of β
(p-value)
R2 ΔR2 ΔF Significance of ΔF
(p-value)
Physical – basic ADL
Step 1 0.0770 0.0770 3.81 0.0117
VAS TIC -0.09 0.5587
SCL-90R depression score -0.07 0.7152
Step 2 0.0789 0.0019 0.28 0.5961
Interaction of VAS TIC and SCL-90R depression score -0.14 0.5961
Physical – intermediate ADL
Step 1 0.2977 0.2977 19.36 <0.0001
VAS TIC -0.16 0.2185
SCL-90R depression score -0.18 0.2872
Step 2 0.3049 0.0072 1.41 0.2372
Interaction of VAS TIC and SCL-90R depression score -0.26 0.2372
Mental health
Step 1 0.5972 0.5972 67.70 <0.0001
VAS TIC -0.01 0.9567
SCL-90R depression score -0.69 <0.0001
Step 2 0.5980 0.0008 0.28 0.6001
Interaction of VAS TIC and SCL-90R depression score -0.09 0.6001
Work performance
Step 1 0.1489 0.1489 4.20 0.0085
VAS TIC 0.14 0.5002
SCL-90R depression score 0.17 0.4910
Step 2 0.1976 0.0487 4.31 0.0514
Interaction of VAS TIC and SCL-90R depression score -0.58 0.0514
Social activities
Step 1 0.2649 0.2649 16.34 <0.0001
VAS TIC -0.07 0.5866
SCL-90R depression score -0.11 0.5390
Step 2 0.2775 0.0126 2.36 0.1271
Interaction of VAS TIC and SCL-90R depression score -0.35 0.1271
Quality of social interactions
Step 1 0.2936 0.2936 18.98 <0.0001
VAS TIC -0.02 0.8817
SCL-90R depression score -0.53 0.0025
Step 2
Interaction of VAS TIC and SCL-90R depression score -0.01 0.2936 0.0000 0.00 0.9486
0.9486
VAS TIC: visual analogue mean scores of severity of Tics; SCL-90R: Symptom Checklist 90 Revised of psychiatric symptoms.
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